| Year |
Citation |
Score |
| 2023 |
Papapetrou EP. Base editors dissect genetic variants in human hematopoietic cells on a large scale. Trends in Immunology. 44: 490-492. PMID 37316391 DOI: 10.1016/j.it.2023.05.009 |
0.426 |
|
| 2023 |
Kotini AG, Carcamo S, Cruz-Rodriguez N, Olszewska M, Wang T, Demircioglu D, Chang CJ, Bernard E, Chao MP, Majeti R, Luo H, Kharas MG, Hasson D, Papapetrou EP. Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia. Blood Cancer Discovery. OF1-OF18. PMID 37067914 DOI: 10.1158/2643-3230.BCD-22-0167 |
0.38 |
|
| 2022 |
Papapetrou EP. MDS/AML with del5q: An acquired "laminopathy"? Cell Stem Cell. 29: 498-499. PMID 35395184 DOI: 10.1016/j.stem.2022.03.008 |
0.324 |
|
| 2022 |
Asimomitis G, Deslauriers AG, Kotini AG, Bernard E, Esposito D, Olszewska M, Spyrou N, Arango Ossa JE, Mortera-Blanco T, Koche RP, Nannya Y, Malcovati L, Ogawa S, Cazzola M, Aaronson SA, ... ... Papapetrou EP, et al. Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs. Blood Advances. PMID 35042235 DOI: 10.1182/bloodadvances.2021006325 |
0.355 |
|
| 2021 |
Alves da Silva PH, Xing S, Kotini AG, Papapetrou EP, Song X, Wucherpfennig KW, Mascarenhas J, Ferrari de Andrade L. MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia. Blood. PMID 34359073 DOI: 10.1182/blood.2021011619 |
0.342 |
|
| 2021 |
Wang T, Pine AR, Kotini AG, Yuan H, Zamparo L, Starczynowski DT, Leslie C, Papapetrou EP. Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. Cell Stem Cell. PMID 33571445 DOI: 10.1016/j.stem.2021.01.011 |
0.34 |
|
| 2021 |
Doulatov S, Papapetrou EP. Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells. Current Opinion in Hematology. 28: 50-56. PMID 33264225 DOI: 10.1097/MOH.0000000000000620 |
0.334 |
|
| 2021 |
Deslauriers AG, Kotini AG, Papapetrou EP. Modeling Leukemia Stem Cells with Patient-Derived Induced Pluripotent Stem Cells. Methods in Molecular Biology (Clifton, N.J.). 2185: 411-422. PMID 33165864 DOI: 10.1007/978-1-0716-0810-4_26 |
0.424 |
|
| 2020 |
Spyrou N, Papapetrou EP. Studying leukemia stem cell properties and vulnerabilities with human iPSCs. Stem Cell Research. 50: 102117. PMID 33388708 DOI: 10.1016/j.scr.2020.102117 |
0.363 |
|
| 2020 |
Doulatov S, Papapetrou EP. Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells. Current Opinion in Hematology. PMID 33278076 DOI: 10.1097/MOH.0000000000000620 |
0.334 |
|
| 2020 |
Kotini AG, Papapetrou EP. Engineering of targeted megabase-scale deletions in human induced pluripotent stem cells. Experimental Hematology. PMID 32544417 DOI: 10.1016/j.exphem.2020.06.001 |
0.34 |
|
| 2020 |
Wesely J, Kotini AG, Izzo F, Luo H, Yuan H, Sun J, Georgomanoli M, Zviran A, Deslauriers AG, Dusaj N, Nimer SD, Leslie C, Landau DA, Kharas MG, Papapetrou EP. Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells. Cell Reports. 31: 107688. PMID 32492433 DOI: 10.1016/J.Celrep.2020.107688 |
0.458 |
|
| 2019 |
Papapetrou EP. Modeling Leukemia with Human Induced Pluripotent Stem Cells. Cold Spring Harbor Perspectives in Medicine. PMID 31451537 DOI: 10.1101/cshperspect.a034868 |
0.38 |
|
| 2019 |
Georgomanoli M, Papapetrou EP. Modeling blood diseases with human induced pluripotent stem cells. Disease Models & Mechanisms. 12. PMID 31171568 DOI: 10.1242/dmm.039321 |
0.429 |
|
| 2018 |
Papapetrou EP. Modeling myeloid malignancies with patient-derived iPSCs. Experimental Hematology. PMID 30481543 DOI: 10.1016/j.exphem.2018.11.006 |
0.376 |
|
| 2018 |
Sperber H, Vora S, Kotini AG, Olszewska M, Wroblewska A, Brown B, Papapetrou EP. Synthetic Lethality CRISPR Screens in Isogenic iPSCs with Splicing Factor Gene Mutations Blood. 132: 3083-3083. DOI: 10.1182/blood-2018-99-111857 |
0.36 |
|
| 2018 |
Wang T, Kotini AG, Papapetrou EP. A "De Novo Leukemogenesis" iPSC Model Charts the Clonal Evolution of Acute Myeloid Leukemia Blood. 132: 773-773. DOI: 10.1182/blood-2018-99-111613 |
0.313 |
|
| 2018 |
Wesely J, Kotini AG, Georgomanoli M, Luo H, Yuan H, Izzo F, Landau DA, Leslie C, Kharas MG, Papapetrou EP. A Novel iPSC Model Reveals a Role for RUNX1 in the Maintenance of AML Leukemia Stem Cells Blood. 132: 772-772. DOI: 10.1182/Blood-2018-99-111506 |
0.456 |
|
| 2018 |
Stokes N, Dominguez-Sola D, Papapetrou EP. Functional Analysis of MYC Deregulation By Diverse Genetic Mechanisms during Hematopoiesis Blood. 132: 1323-1323. DOI: 10.1182/blood-2018-99-110829 |
0.426 |
|
| 2017 |
Verma N, Pan H, Doré LC, Shukla A, Li QV, Pelham-Webb B, Teijeiro V, González F, Krivtsov A, Chang CJ, Papapetrou EP, He C, Elemento O, Huangfu D. Publisher Correction: TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells. Nature Genetics. PMID 29255266 DOI: 10.1038/s41588-017-0024-5 |
0.348 |
|
| 2017 |
Verma N, Pan H, Doré LC, Shukla A, Li QV, Pelham-Webb B, Teijeiro V, González F, Krivtsov A, Chang CJ, Papapetrou EP, He C, Elemento O, Huangfu D. Author Correction: TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells. Nature Genetics. PMID 29255265 DOI: 10.1038/S41588-017-0025-4 |
0.316 |
|
| 2017 |
Verma N, Pan H, Doré LC, Shukla A, Li QV, Pelham-Webb B, Teijeiro V, González F, Krivtsov A, Chang CJ, Papapetrou EP, He C, Elemento O, Huangfu D. TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells. Nature Genetics. PMID 29203910 DOI: 10.1038/S41588-017-0002-Y |
0.369 |
|
| 2017 |
Papapetrou EP. Gene and Cell Therapy for β-Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier. Advances in Experimental Medicine and Biology. 1013: 219-240. PMID 29127683 DOI: 10.1007/978-1-4939-7299-9_9 |
0.418 |
|
| 2017 |
Kotini AG, Chang CJ, Chow A, Yuan H, Ho TC, Wang T, Vora S, Solovyov A, Husser C, Olszewska M, Teruya-Feldstein J, Perumal D, Klimek VM, Spyridonidis A, Rampal RK, ... ... Papapetrou EP, et al. Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell. PMID 28215825 DOI: 10.1016/J.Stem.2017.01.009 |
0.305 |
|
| 2017 |
Stavrou EF, Lazaris VM, Giannakopoulos A, Papapetrou E, Spyridonidis A, Zoumbos NC, Gkountis A, Athanassiadou A. The β-globin Replicator greatly enhances the potential of S/MAR based episomal vectors for gene transfer into human haematopoietic progenitor cells. Scientific Reports. 7: 40673. PMID 28106085 DOI: 10.1038/Srep40673 |
0.479 |
|
| 2016 |
Kotini AG, Sadelain M, Papapetrou EP. LiPS-A3S, a human genomic site for robust expression of inserted transgenes. Molecular Therapy. Nucleic Acids. 5: e394. PMID 28427140 DOI: 10.1038/mtna.2016.99 |
0.637 |
|
| 2016 |
Kotini AG, Sadelain M, Papapetrou EP. LiPS-A3S, a human genomic site for robust expression of inserted transgenes. Molecular Therapy. Nucleic Acids. 5: e394. PMID 28131289 DOI: 10.1038/mtna.2016.99 |
0.637 |
|
| 2016 |
Papapetrou EP. Patient-derived induced pluripotent stem cells in cancer research and precision oncology. Nature Medicine. 22: 1392-1401. PMID 27923030 DOI: 10.1038/nm.4238 |
0.336 |
|
| 2016 |
Kotini AG, Sadelain M, Papapetrou EP. LiPS-A3S, a human genomic site for robust expression of inserted transgenes. Molecular Therapy. Nucleic Acids. 5: e394. PMID 27898090 DOI: 10.1038/Mtna.2016.99 |
0.637 |
|
| 2016 |
Papapetrou EP. Induced pluripotent stem cells, past and future. Science (New York, N.Y.). 353: 991-992. PMID 27701103 DOI: 10.1126/science.aai7626 |
0.409 |
|
| 2016 |
Kotini AG, de Stanchina E, Themeli M, Sadelain M, Papapetrou EP. Escape Mutations, Ganciclovir Resistance, and Teratoma Formation in Human iPSCs Expressing an HSVtk Suicide Gene. Molecular Therapy. Nucleic Acids. 5: e284. PMID 26836371 DOI: 10.1038/Mtna.2015.57 |
0.625 |
|
| 2016 |
Chang C, Kotini A, Teruya-Feldstein J, Abdel-Wahab O, Bradley R, Papapetrou EP. Isogenic iPSC Models of SRSF2-Mutant Myelodysplastic Syndrome Capture Disease Phenotypes, Splicing Defects and Drug Responses Blood. 128: 962-962. DOI: 10.1182/Blood.V128.22.962.962 |
0.346 |
|
| 2016 |
Ruiz-Gutierrez M, Vargel Bolukbasi O, Vo L, Sugimura R, Sanchez Bonilla M, Kotini A, Novina CD, Daley GQ, Papapetrou EP, Shimamura A. Modeling Bone Marrow Failure and MDS in Shwachman Diamond Syndrome Using Induced Pluripotent Stem Cells Blood. 128: 1496-1496. DOI: 10.1182/Blood.V128.22.1496.1496 |
0.334 |
|
| 2015 |
Saydaminova K, Ye X, Wang H, Richter M, Ho M, Chen H, Xu N, Kim JS, Papapetrou E, Holmes MC, Gregory PD, Palmer D, Ng P, Ehrhardt A, Lieber A. Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing site-specific endonucleases under microRNA regulation. Molecular Therapy. Methods & Clinical Development. 1: 14057. PMID 26052525 DOI: 10.1038/Mtm.2014.57 |
0.521 |
|
| 2015 |
Kotini AG, Chang CJ, Boussaad I, Delrow JJ, Dolezal EK, Nagulapally AB, Perna F, Fishbein GA, Klimek VM, Hawkins RD, Huangfu D, Murry CE, Graubert T, Nimer SD, Papapetrou EP. Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nature Biotechnology. 33: 646-55. PMID 25798938 DOI: 10.1038/Nbt.3178 |
0.309 |
|
| 2015 |
Perna F, Vu LP, Themeli M, Kriks S, Hoya-Arias R, Khanin R, Hricik T, Mansilla-Soto J, Papapetrou EP, Levine RL, Studer L, Sadelain M, Nimer SD. The polycomb group protein L3MBTL1 represses a SMAD5-mediated hematopoietic transcriptional program in human pluripotent stem cells. Stem Cell Reports. 4: 658-69. PMID 25754204 DOI: 10.1016/J.Stemcr.2015.02.003 |
0.597 |
|
| 2015 |
Saydaminova K, Wang H, Ye X, Chen H, Xu N, Kim J, Papapetrou E, Holmes MC, Gregory PD, Palmer D, Ng P, Kiem H, Ehrhardt A, Lieber A. 123. Helper-Dependent Ad5/35 Vectors for ZFN Mediated Gene Editing in Hematopoietic Stem Cells Molecular Therapy. 23: S51. DOI: 10.1016/S1525-0016(16)33728-5 |
0.476 |
|
| 2015 |
Papapetrou E. Modeling myeloid malignancies with human induced pluripotent stem cells Experimental Hematology. 43: S39. DOI: 10.1016/J.Exphem.2015.06.039 |
0.498 |
|
| 2014 |
Oricchio E, Papapetrou EP, Lafaille F, Ganat YM, Kriks S, Ortega-Molina A, Mark WH, Teruya-Feldstein J, Huse JT, Reuter V, Sadelain M, Studer L, Wendel HG. A cell engineering strategy to enhance the safety of stem cell therapies. Cell Reports. 8: 1677-85. PMID 25242333 DOI: 10.1016/J.Celrep.2014.08.039 |
0.572 |
|
| 2014 |
Kotini A, Delrow JJ, Graubert TA, Nimer S, Papapetrou EP. Functional Dissection of Chromosome 7q Loss and Haploinsufficient Gene Discovery Using iPSC Models of MDS Blood. 124: 524-524. DOI: 10.1182/Blood.V124.21.524.524 |
0.336 |
|
| 2013 |
Boussaad I, Kotini A, Dolezal EK, Nimer S, Papapetrou EP. An iPSC-Based Model Of MDS For Phenotype-Driven Gene and Drug Discovery Blood. 122: 859-859. DOI: 10.1182/blood.v122.21.859.859 |
0.361 |
|
| 2012 |
Hammachi F, Morrison GM, Sharov AA, Livigni A, Narayan S, Papapetrou EP, O'Malley J, Kaji K, Ko MS, Ptashne M, Brickman JM. Transcriptional activation by Oct4 is sufficient for the maintenance and induction of pluripotency. Cell Reports. 1: 99-109. PMID 22832160 DOI: 10.1016/J.Celrep.2011.12.002 |
0.41 |
|
| 2012 |
Sadelain M, Papapetrou EP, Bushman FD. Safe harbours for the integration of new DNA in the human genome. Nature Reviews. Cancer. 12: 51-8. PMID 22129804 DOI: 10.1038/Nrc3179 |
0.481 |
|
| 2012 |
Perna F, Vu LP, Themeli M, Hoya-Arias R, Liu F, Wang L, Gurvich N, Hricik T, Papapetrou EP, Moore MAA, Levine RL, Sadelain M, Nimer S. L3MBTL1: A Polycomb Protein At the Node of Crosstalk Between the BMP4 and Hippo Signaling Pathways in Erythropoiesis. Blood. 120: 2296-2296. DOI: 10.1182/Blood.V120.21.2296.2296 |
0.577 |
|
| 2012 |
Boussaad I, Dolezal EK, Perna F, Nimer SD, Papapetrou EP. IPS Cells From Del(7q)-MDS Patients Display Impaired Proliferation and Hematopoietic Commitment Blood. 120: 174-174. DOI: 10.1182/blood.V120.21.174.174 |
0.312 |
|
| 2011 |
Papapetrou EP, Sadelain M. Derivation of genetically modified human pluripotent stem cells with integrated transgenes at unique mapped genomic sites. Nature Protocols. 6: 1274-89. PMID 21886096 DOI: 10.1038/Nprot.2011.362 |
0.611 |
|
| 2011 |
Papapetrou EP, Sadelain M. Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector. Nature Protocols. 6: 1251-73. PMID 21886095 DOI: 10.1038/Nprot.2011.374 |
0.612 |
|
| 2011 |
Kim H, Lee G, Ganat Y, Papapetrou EP, Lipchina I, Socci ND, Sadelain M, Studer L. miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells. Cell Stem Cell. 8: 695-706. PMID 21624813 DOI: 10.1016/J.Stem.2011.04.002 |
0.591 |
|
| 2011 |
Brady T, Roth SL, Malani N, Wang GP, Berry CC, Leboulch P, Hacein-Bey-Abina S, Cavazzana-Calvo M, Papapetrou EP, Sadelain M, Savilahti H, Bushman FD. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Research. 39: e72. PMID 21415009 DOI: 10.1093/Nar/Gkr140 |
0.509 |
|
| 2011 |
Müller FJ, Schuldt BM, Williams R, Mason D, Altun G, Papapetrou EP, Danner S, Goldmann JE, Herbst A, Schmidt NO, Aldenhoff JB, Laurent LC, Loring JF. A bioinformatic assay for pluripotency in human cells. Nature Methods. 8: 315-7. PMID 21378979 DOI: 10.1038/nmeth.1580 |
0.494 |
|
| 2011 |
Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, Leslie C, Bushman FD, Studer L, Sadelain M. Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells. Nature Biotechnology. 29: 73-8. PMID 21151124 DOI: 10.1038/Nbt.1717 |
0.661 |
|
| 2011 |
Papapetrou EP, Sadelain M, Bushman F. Genomic Safe Harbors in Human iPS Cells Blood. 118: SCI-47-SCI-47. DOI: 10.1182/Blood.V118.21.Sci-47.Sci-47 |
0.621 |
|
| 2011 |
Perna F, Vu LP, Themeli M, Hoya-Arias R, Zhao X, Papapetrou EP, Sadelain M, Nimer SD. Targeting a Novel Epigenetic Silencing Mechanism to Efficiently Upregulate Fetal Globin Gene Expression Blood. 118: 352-352. DOI: 10.1182/Blood.V118.21.352.352 |
0.601 |
|
| 2010 |
Papapetrou EP, Sadelain M. Reconstructing blood from induced pluripotent stem cells. F1000 Medicine Reports. 2. PMID 20948840 DOI: 10.3410/M2-44 |
0.605 |
|
| 2010 |
Yang JS, Maurin T, Robine N, Rasmussen KD, Jeffrey KL, Chandwani R, Papapetrou EP, Sadelain M, O'Carroll D, Lai EC. Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proceedings of the National Academy of Sciences of the United States of America. 107: 15163-8. PMID 20699384 DOI: 10.1073/Pnas.1006432107 |
0.425 |
|
| 2010 |
Papapetrou EP, Korkola JE, Sadelain M. A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells. Stem Cells (Dayton, Ohio). 28: 287-96. PMID 19911427 DOI: 10.1002/Stem.257 |
0.452 |
|
| 2010 |
Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, Leslie C, Bushman F, Studer L, Sadelain M. Therapeutic Transgene Expression From Genomic Safe Harbors In Patient-Specific Induced Pluripotent Stem Cells Blood. 116: 564-564. DOI: 10.1182/Blood.V116.21.564.564 |
0.617 |
|
| 2009 |
Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, Ganat YM, Menon J, Shimizu F, Viale A, Tabar V, Sadelain M, Studer L. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature. 461: 402-6. PMID 19693009 DOI: 10.1038/Nature08320 |
0.538 |
|
| 2009 |
Papapetrou EP, Tomishima MJ, Chambers SM, Mica Y, Reed E, Menon J, Tabar V, Mo Q, Studer L, Sadelain M. Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proceedings of the National Academy of Sciences of the United States of America. 106: 12759-64. PMID 19549847 DOI: 10.1073/Pnas.0904825106 |
0.602 |
|
| 2009 |
Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nature Biotechnology. 27: 275-80. PMID 19252484 DOI: 10.1038/Nbt.1529 |
0.568 |
|
| 2009 |
Papapetrou EP, Kovalovsky D, Beloeil L, Sant'angelo D, Sadelain M. Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. The Journal of Clinical Investigation. 119: 157-68. PMID 19033646 DOI: 10.1172/Jci37216 |
0.516 |
|
| 2009 |
Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Erratum: Corrigendum: Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling Nature Biotechnology. 27: 485-485. DOI: 10.1038/Nbt0509-485A |
0.487 |
|
| 2008 |
Papapetrou E, Kovalovsky D, Beloeil L, Sant'angelo D, Sadelain M. MicroRNA regulation directs lineage- and developmental stage-specific transgene expression in hematopoietic stem cell progeny Blood Cells, Molecules, and Diseases. 40: 280. DOI: 10.1016/J.Bcmd.2007.10.068 |
0.626 |
|
| 2006 |
Papapetrou EP, Ziros PG, Micheva ID, Zoumbos NC, Athanassiadou A. Gene transfer into human hematopoietic progenitor cells with an episomal vector carrying an S/MAR element. Gene Therapy. 13: 40-51. PMID 16094410 DOI: 10.1038/sj.gt.3302593 |
0.459 |
|
| 2005 |
Papapetrou EP, Zoumbos NC, Athanassiadou A. Genetic modification of hematopoietic stem cells with nonviral systems: past progress and future prospects. Gene Therapy. 12: S118-30. PMID 16231044 DOI: 10.1038/sj.gt.3302626 |
0.371 |
|
| Show low-probability matches. |